(KYMA, KECY) - Pfizer and BioNTech have asked the food and drug administration for emergency use authorization for their COVID-19 vaccine in children ages six months to five years.
Trial results released last week show the vaccine appears safe and has a strong immune response.
A month after the children in the trial got their third dose, tests showed the vaccine produced a similar immune response as two doses in 16- to 25-year-olds..
Trial results also show the vaccine had an 80.3% efficacy rate against symptomatic COVID-19 in this youngest age group.
However, more testing is needed to finalize the efficacy rate.